Benign Prostatic Hyperplasia Devices

Benign Prostatic Hyperplasia Devices

Benign prostatic hyperplasia devices are medical devices used in the treatment of an enlarged prostate, a condition known as benign prostatic hyperplasia. Lower urinary tract symptoms such as frequent urination, difficulty initiating or maintaining urination, weak urine stream, and the sensation of incomplete bladder emptying are all common in older men with BPH.

The Benign Prostatic Hyperplasia Devices Market is expected to grow at a strong CAGR of 6.95% during the forecast period (2023-2030) owing to the rising demand for benign prostatic hyperplasia devices, as the growing geriatric population, mainly the aging male segment. As per the World Bank, in 2022, around 345,324,995 number of population ages 65 and above of male. Adding to this, the market is anticipated to expand in the forecast years due to the advances in medical technology that have led to the development of more efficient and less invasive BPH devices, improving patient outcomes and reducing recovery times. For instance, in September 2021, Olympus was chosen to display the iTind device, a briefly embedded device for the help of enlarged prostate side effects, at the Vizient Innovative Technology Exchange.

• Based on the device type, the market is segmented into transurethral resection of the prostate (TURP), transurethral needle ablation (TUNA), transurethral incision of the prostate (TUIP), transurethral microwave thermotherapy (TUMT), laser therapy, electrosurgery, and others. Amongst these, the transurethral resection of the prostate segment dominated the market in 2022. This is mainly used to remove the excess tissue causing urinary issues and to improve the patient’s quality of life. TURP is a well-established surgical procedure used to treat symptomatic BPH, a non-cancerous enlargement of the prostate gland commonly found in aging men.
• By technology, the market is segmented into radiofrequency ablation devices, resectoscopes, urology lasers, prostatic stents, and implants. Among these, urology lasers are expected to grow with a significant CAGR during the forecast period (2023-2030). The use of urology lasers such as holmium lasers and GreenLight lasers, in benign prostatic hyperplasia device treatment offers few advantages over conventional surgeries, including less blood loss, shorter recovery time, and reduced chance of complications. As per Boston Scientific Corporation, above one million men worldwide have been treated with GreenLight Laser Therapy for BPH in 2023.
• On the basis of end-users, the market is segmented into hospitals, ambulatory surgical centers, and physician offices. The hospital category is expected to grow at a substantial CAGR during the forecasted period (2023-2030). This is mainly due to the rise prevalence of benign prostatic hyperplasia among hospitalized patients. Besides, hospitals are investing in advanced technologies and equipment for the diagnosis and treatment of BPH, which is also driving the growth of the BPH device market.
• For a better understanding of the market adoption of the benign prostatic hyperplasia devices industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Rest of World. North America dominated the benign prostatic hyperplasia devices market in 2022. BPH is a prevalent condition among aging men, and North America, comprising the United States and Canada, has a large population of men in the target age group. As per the World Bank data, in 2022, around 25,824,830 and 3,424,483 number of population ages 65 and above of male in the United States and Canada respectively. This demographic factor has been a key driver of market growth in the North American region. Moreover, North America has a well-established healthcare infrastructure and access to advanced medical technologies, which have contributed to the development and adoption of innovative BPH devices. For instance, in April 2022, Teleflex Incorporated announced the launch of the UroLift System in Japan for treating benign prostatic hyperplasia (BPH), or enlarged prostate.
• Some of the major players operating in the market include Olympus Corporation, Boston Scientific Corporation, Butterfly, SRS Medical, Teleflex Incorporated, Urotronic, Zenflow, Inc., ProArc, and Medeon Biodesign, Inc, Urologix, LLC.

Show more